Compare GILT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | AMLX |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1997 | 2021 |
| Metric | GILT | AMLX |
|---|---|---|
| Price | $15.61 | $13.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $19.00 | ★ $21.56 |
| AVG Volume (30 Days) | 868.4K | ★ 992.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $11.72 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $5.46 | $4.64 |
| 52 Week High | $20.99 | $18.61 |
| Indicator | GILT | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 39.29 |
| Support Level | $13.38 | $13.36 |
| Resistance Level | $18.84 | $15.37 |
| Average True Range (ATR) | 1.11 | 0.79 |
| MACD | -0.38 | -0.17 |
| Stochastic Oscillator | 11.00 | 26.44 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.